Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is a P2Y12 platelet inhibitor used to reduce the risk of thrombotic cardiovascular events. It is a direct-acting, reversible antagonist of the P2Y12 receptor.
## Primary Indications
* Reduction of thrombotic cardiovascular events (including myocardial infarction and stroke) in patients with acute coronary syndrome (ACS).
* Reduction of new thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) and multiple risk factors for cardiovascular events.
## Adult Dosing
* **Acute Coronary Syndrome (ACS):** 180 mg orally once as a single loading dose, followed by 90 mg orally twice daily.
* **Patients with history of MI and multiple risk factors:** 90 mg orally twice daily.
* **Duration of therapy:** Typically for at least 12 months, or as guided by clinical assessment of risk/benefit. In patients treated with a coronary stent, the duration may be guided by stent type and patient factors.
## Pediatric Dosing
No established pediatric dosing.
## Dose Adjustments
No specific dose adjustments are recommended for hepatic or renal impairment. However, caution is advised in patients with moderate-to-severe hepatic impairment.
## Contraindications
* Active bleeding.
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any component of the formulation.
* Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) is generally contraindicated due to increased risk of bleeding.
## Adverse Effects
* **Common:** Dyspnea, bruising, bleeding (including major and minor).
* **Serious:** Major bleeding, including intracranial and fatal bleeding. Ventricular pauses.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with CYP3A4 substrates (e.g., simvastatin, atorvastatin) may increase the exposure of these drugs. Consider dose reduction of the coadministered CYP3A4 substrate.
* **CYP3A4 Inducers:** Concurrent use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) may decrease ticagrelor exposure and efficacy.
* **Other Antithrombotics:** Increased risk of bleeding when used with other anticoagulants (e.g., warfarin, direct oral anticoagulants) or antiplatelet agents.
## Monitoring
* Monitor for signs and symptoms of bleeding.
* Monitor for signs and symptoms of dyspnea.
* Consider assessment of bleeding risk versus thrombotic risk when deciding on duration of therapy.
## Clinical Pearls
* Ticagrelor is a reversible P2Y12 inhibitor, unlike clopidogrel and prasugrel which are irreversible.
* Dyspnea is a common side effect, often transient and not indicative of underlying cardiac or pulmonary disease, but warrants assessment.
* Avoid concurrent use of ticagrelor with prasugrel or clopidogrel.
* Dosing of aspirin should be limited to a low daily dose (e.g., 75-100 mg) in patients receiving ticagrelor for ACS or secondary prevention after MI, as higher doses have been associated with increased bleeding risk without added cardiovascular benefit.
***
**Disclaimer:** This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for complete details and to ensure patient-specific care.
